BPC-157 Arginate

Background

BPC‑157 arginate (often referred to in non‑regulated markets as “stable BPC‑157”) is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, originally identified as a fragment of a larger protein in human gastric juice.[1][7][12] It belongs to a class of gastric cytoprotective peptides and has been investigated for organoprotection, wound healing, and neuromuscular and cardiovascular indications in preclinical models.[7][11][12]

The arginate designation refers to salt formation with arginine (BPC‑157·arginine) to improve aqueous stability and solubility, analogous to other peptide counter‑ions; however, most peer‑reviewed literature characterizes the base peptide (BPC‑157) without specifying the salt form.[1][7][12] Publications frequently describe BPC‑157 as “stable gastric pentadecapeptide”, referencing its resistance to degradation in gastric juice and its relative physicochemical stability compared with many other peptides.[7][11]

BPC‑157 has been studied in animal models since the early 1990s, primarily by a few research groups, and has been evaluated in limited early clinical settings as an anti‑ulcer peptide and in small trials for inflammatory bowel disease and musculoskeletal pain, though detailed results remain largely unpublished or only summarized in reviews.[1][6][8][12] As of recent systematic and regulatory reviews, there are no completed Phase II or Phase III trials and no approved medicinal product containing BPC‑157 in the US or EU.[1][2][12]

Mechanism of action

BPC‑157 is described as a pleiotropic cytoprotective peptide acting on multiple molecular pathways rather than a single defined receptor target.[7][11][12]

Key mechanistic themes from preclinical work include:

• Endothelial and epithelial protection: BPC‑157 supports endothelium maintenance and collateral vessel recruitment, proposed to restore microcirculation and protect against ischemia–reperfusion injury in models of major vessel occlusion, Budd–Chiari syndrome, and Pringle maneuver–related hepatic ischemia.[7][11]
• Nitric oxide (NO) system modulation: Studies in rat models indicate that BPC‑157 interacts functionally with the L‑arginine–NO pathway, normalizing disturbances induced by L‑NAME (NO synthase inhibitor) or L‑arginine and modulating expression of NOS‑related genes (Nos1, Nos2).[7][11][13] These data suggest an indirect effect on eNOS/Src–Caveolin‑1 signaling, with downstream influence on vasomotor tone and thrombosis.[11][13]
• VEGF and growth factor regulation: BPC‑157 has been reported to influence VEGF signaling and angiogenesis, contributing to wound and tendon healing in animal and in vitro models.[6][7][12]
• Anti‑inflammatory and membrane‑stabilizing actions: It reduces inflammatory damage and preserves cell membrane integrity in gastrointestinal, hepatic, and nervous tissue injury models.[7][11][12]
• Neuroprotective and neuromodulatory effects: In CNS models, BPC‑157 demonstrates protection in traumatic brain and spinal cord injury and modulates behavior in rodent models of anxiety, depression, seizures, and “negative‑like” schizophrenia symptoms, with associated changes in gene expression for multiple signaling pathways.[4][8][13]
• Enzyme interactions (AChE): BPC‑157 is a competitive, low‑potency inhibitor of acetylcholinesterase (Ki ≈ 0.48 mM; IC50 ≈ 2.8 mM), far weaker than approved AChE inhibitors, suggesting limited direct therapeutic relevance but demonstrating potential for hybrid analog development.[3]

Overall, the mechanism of action is multifactorial and incompletely defined, with convergence on vascular protection, NO/VEGF modulation, and anti‑inflammatory cytoprotection.[1][7][11][12]

Evidence summary

Preclinical evidence

A large body of rodent and other animal studies underpins current knowledge:[1][2][4][7][8][11][12]

• Vascular and organ protection

  • In models of major vessel occlusion, hepatic ischemia–reperfusion (Pringle maneuver), and Budd–Chiari syndrome, BPC‑157 improved survival, restored blood flow via collateral vessel recruitment, and reduced multiorgan failure.[7][11]
  • Dosing in these studies typically ranged from 10 ng/kg to 10 µg/kg, administered intraperitoneally or orally, but dose–response relationships and PK–PD correlations remain poorly defined.[1][7][11]

• Spinal cord and nervous system injury

  • A rat spinal cord compression model (L2–L3) evaluated single intraperitoneal doses of 200 or 2 µg/kg BPC‑157 applied 10 minutes post‑injury (sample size not clearly specified in the abstract, described as multiple rats per group).[8] BPC‑157‑treated animals showed:
    • Earlier and more complete functional motor recovery (tail function, reduced spasticity).
    • Reduced pathological changes such as axonal loss, edema, and motoneuron loss compared with saline controls over follow‑up to 360 days.[8]
  • Additional FASEB abstract data report oral BPC‑157 in drinking water (≈10 ng/kg/day for 8 weeks) counteracting spinal instability after bilateral facetectomy in rats, improving radiologic and functional parameters compared with controls.[9]

• Gastrointestinal and fistula healing

  • In an esophagocutaneous fistula rat model, BPC‑157 significantly accelerated fistula closure and improved histologic healing compared with controls; reported doses ranged from low nanogram to microgram/kg intraperitoneally or per os.[10]

• Cardiovascular models

  • A comprehensive review of cardiology‑related studies notes beneficial effects in myocardial infarction, heart failure, pulmonary hypertension, and arrhythmias, primarily in rat models.[11] Improvements include reduced infarct size, attenuation of heart failure signs, and anti‑thrombotic effects, again at low microgram‑to‑nanogram/kg doses via parenteral or oral routes.[11]

• Wound, tendon, and bone healing

  • Multiple studies summarized in reviews show accelerated healing of skin wounds, muscle, tendon, and bone, with improved biomechanical properties and connective tissue organization.[2][6][12]

Pharmacokinetic studies in rats and dogs using radiolabeled BPC‑157 demonstrate rapid distribution and extensive metabolism into smaller peptides and amino acids, with excretion via urine and bile; the peptide itself shows low systemic persistence, highlighting a PK–PD disconnect relative to the long‑lasting biological effects reported.[14][1]

Human data

Human evidence remains limited and incompletely published:

• A 2026 narrative review of BPC‑157 as an investigational peptide reported no completed Phase II clinical trial, no defined therapeutic dose, and no regulatory‑grade clinical development program.[1]
• A wound‑healing and sports medicine–focused review notes “limited human trials” evaluating BPC‑157 for knee pain and for intravenous safety, but provides no large randomized controlled trial data, and detailed protocols or outcomes are not publicly available in indexed sources.[6]
• A broader literature and patent review confirms only preliminary clinical experiences, primarily small, early‑phase studies in gastrointestinal indications (e.g., inflammatory bowel disease, anti‑ulcer therapy) and neurology (e.g., multiple sclerosis), with scant peer‑reviewed outcome data.[8][9][12]

Thus, current understanding is dominated by animal models; there is no high‑quality human efficacy evidence supporting any indication.[1][2][6][12]

Clinical and research uses

Investigational and proposed indications

Based on preclinical data and speculative work, BPC‑157 (including arginate forms) has been proposed for:

• Gastrointestinal mucosal protection and inflammatory bowel disease (anti‑ulcer peptide concept).[1][7][12]
• Soft‑tissue and tendon injuries, musculoskeletal recovery in sports medicine.[2][6]
• Neurotrauma and neurodegenerative conditions, including spinal cord injury, traumatic brain injury, and experimental “negative‑like” schizophrenia models.[4][8][13]
• Cardiovascular disorders such as myocardial infarction, heart failure, arrhythmias, and thrombosis.[11]
• COVID‑19 and other systemic inflammatory states, largely hypothesized on the basis of endothelial and anti‑inflammatory properties.[15]

These uses are preclinical or hypothetical; no indication has regulatory approval.[1][2][11][12]

Off‑label and non‑regulated use

Reviews of sports medicine and “grey‑zone” pharmacology note that BPC‑157 is widely sold as a “research chemical” and used anecdotally by athletes for tendon and ligament injury recovery, despite the absence of approved medical indications.[2][6] The World Anti‑Doping Agency (WADA) lists BPC‑157 as a banned substance (Class S0, unapproved substances).[2]

Dosing context

There is no validated therapeutic dosing regimen for BPC‑157 or BPC‑157 arginate in humans.[1] Available information reflects experimental dosing in animals and limited early‑phase human work:

• Animal studies commonly employ:
  • 10 ng/kg to 10 µg/kg per day, given intraperitoneally, orally, or intragastrically, sometimes as a single post‑injury dose (e.g., 2–200 µg/kg IP in spinal cord injury) or continuous administration in drinking water (~10 ng/kg/day) over weeks.[7][8][9][11]
• Human data:
  • Narrative and systematic reviews state that dose ranges, frequency, and treatment duration are not standardized, and no dose–response studies or formal Phase II trials have been reported.[1][6][12]

Any dosages described in the literature are experimental and not suitable as clinical recommendations.

Safety profile

Preclinical safety

Across numerous animal studies, BPC‑157 has shown a wide apparent safety margin, with some reports stating that a lethal dose (LD₁) has not been achieved in tested models.[7][8][9][11][12] Toxicology‑focused summaries note:

• Absence of acute mortality at doses far exceeding those used therapeutically in animals.[8][9][12]
• No major organ toxicity reported in histopathologic evaluations across gastrointestinal, hepatic, renal, cardiac, and CNS tissues at experimental doses.[7][11][12]

However, formal regulatory‑standard GLP toxicology programs (e.g., full reproductive, genotoxicity, carcinogenicity panels) are not publicly documented.[1][12]

Human safety

Reviews citing limited clinical exposure describe BPC‑157 as having a generally favorable short‑term safety profile, with few reported side effects in early human use.[6][12] Reported or theorized adverse effects include:

• Transient local injection‑site reactions (from non‑regulated use; not systematically studied).[2][6]
• Unknown long‑term risks, including potential effects on aberrant angiogenesis, tumor biology, or immune modulation, given its pro‑healing and VEGF‑modulating properties; these concerns are theoretical and not resolved by current data.[1][6][12]

Because clinical exposure is limited and poorly documented, the true incidence of adverse events, rare toxicities, and drug interactions remains unknown.[1][6][12]

Contraindications and cautions

No formal, label‑based contraindications exist because there is no approved medicinal product. Based on mechanism and preclinical profile, expert reviews highlight areas of uncertainty rather than confirmed contraindications:[1][2][6][12]

• Use in pregnancy, lactation, children, or patients with malignancy has not been evaluated.
• Potential interactions with antithrombotic therapies and NO‑modulating drugs are unknown, given BPC‑157’s influence on NO and vascular function.[11][13]

In the absence of controlled human data, safety in any population cannot be assumed.

Regulatory status

• United States / European Union: Recent biopharmaceutical and translational reviews state that BPC‑157 is not approved as a drug by the FDA or EMA, and there is no authorized pharmaceutical formulation.[1][2][12]
• Development stage: As of the latest comprehensive review, there are no completed Phase II trials, no defined target indication, and significant regulatory and translational barriers, including unclear IP position, incomplete toxicology, and poorly characterized pharmacokinetics.[1]
• Doping regulation: The World Anti‑Doping Agency lists BPC‑157 among prohibited substances under Class S0 (unapproved substances), meaning its use is banned in elite sport regardless of route of administration.[2]

BPC‑157 arginate (stable BPC‑157) is therefore best characterized as an investigational, unapproved peptide with extensive preclinical but minimal human evidence and no current therapeutic authorization in the US or EU.[1][2][6][12]